Merck & Co., Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Merck & Co., Inc. (MRK) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $33.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-27.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2014-02-27
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2013 was $33.00M, a 55.41% decline from fiscal 2012.
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2012 was $74.00M.
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2011 was -$10.00M, a 124.39% decline from fiscal 2010.
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2010 was $41.00M, a 80.29% decline from fiscal 2009.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|
| 2013-12-31 | $33.00M 10-K · filed 2014-02-27 |
| 2012-12-31 | $74.00M 10-K · filed 2014-02-27 |
| 2011-12-31 | -$10.00M 10-K · filed 2014-02-27 |
| 2010-12-31 | $41.00M 10-K · filed 2013-02-28 |
| 2009-12-31 | $208.00M 10-K · filed 2012-02-28 |
| 2008-12-31 | -$213.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |